<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Amphiregulin (AREG) and Epiregulin (EREG), ligands of EGFR, are reported to be predictive biomarkers of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients treated with Cetuximab, an anti-EGFR antibody </plain></SENT>
<SENT sid="1" pm="."><plain>The purpose of this study is to determine the correlation of AREG and EREG expression between primary <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and corresponding <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: One hundred twenty <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients with <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> (100 with synchronous <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e>, 20 with metachronous) were evaluated </plain></SENT>
<SENT sid="3" pm="."><plain>No patients had ever received anti-EGFR antibody agents </plain></SENT>
<SENT sid="4" pm="."><plain>AREG and EREG <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression from both the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> and <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> were measured using real-time RT-PCR </plain></SENT>
<SENT sid="5" pm="."><plain>KRAS codon 12, 13 mutation status was analyzed by direct sequencing </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Modest, but significant, correlations were observed between <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> and corresponding <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> in both AREG <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression (Rs = 0.54, p &lt; 0.0001) and EREG <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression (Rs = 0.58, p &lt; 0.0001) </plain></SENT>
<SENT sid="7" pm="."><plain>AREG and EREG <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression was strongly correlated in both the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> (Rs = 0.81, p &lt; 0.0001) and the <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> (Rs = 0.87, p &lt; 0.0001) </plain></SENT>
<SENT sid="8" pm="."><plain>No significant survival difference was observed between low and high AREG or EREG patients when <z:hpo ids='HP_0000001'>all</z:hpo> 120 patients were analyzed </plain></SENT>
<SENT sid="9" pm="."><plain>However, when divided by KRAS status, KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> patients with low EREG <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels in the primary site showed significantly better overall survival rates than those with high levels (p = 0.018) </plain></SENT>
<SENT sid="10" pm="."><plain>In multivariate analysis, low EREG expression was significantly associated with better overall survival (p = 0.006) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: AREG and EREG expression showed a modest correlation between <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> and <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>As EREG <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression was associated with decreased survival, it is appeared to be a useful prognostic marker in KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> patients who never received anti-EGFR therapy </plain></SENT>
</text></document>